Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

England, E; Rees, DG; Scott, IC; Carmen, S; Chan, DTY; Huntington, CC; Houslay, KF; Erngren, T; Penney, M; Majithiya, JB; Rapley, L; Sims, DA; Hollins, C; Hinchy, EC; Strain, MD; Kemp, BP; Corkill, DJ; May, RD; Vousden, KA; Butler, RJ; Mustelin, T; Vaughan, TJ; Lowe, DC; Colley, C; Cohen, ES

Cohen, ES (通讯作者)，AstraZeneca, Res & Early Dev, Resp & Immunol, BioPharmaceut R&D,Biosci Asthma & Skin Immun, Cambridge, England.

SCIENTIFIC REPORTS, 2023; 13 (1):

Abstract

Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索